Geoff Martha: Thanks, Mike. I mean, I know there’s a lot of interest in this. And look, I just emphasize Mike’s comments. Step one was to have a robot that has the capabilities and strong physician acceptance. And we feel strongly that we have that. And now we’re building up our experience primarily in Europe and of operating of the robot out in the wild and then really, as Mike mentioned, building out that instrument portfolio and executing on the U.S. trial so that we can launch in the U.S. That will be between the U.S. and some new instruments that will really drive a lot of growth here. So anyway, more to come on that. But thanks for the question, Vijay.
Ryan Weispfenning: Yes, thanks, Vijay. Next question, please Brad.
Brad Welnick: The next question comes from Kristen Stewart with CL King. Kristen, please go ahead.
Kristen Stewart: Hey, thanks for taking my questions. I was just wondering if you could provide any updates on the patient monitoring respiratory interventions spin?
Karen Parkhill: Yes. Thanks, Kristen, for the question. We’re continuing to work on the separation of that and our focus through all of it is to maximize shareholder value. No big updates.
Kristen Stewart: Perfect. Thanks very much.
Ryan Weispfenning: Thanks, Kristen. Next question, please.
Brad Welnick: The next question comes from Matt O’Brien at Piper Sandler. Matt, please go ahead.
Matt O’Brien: Good morning. Can you hear me okay? Hey could you guys hear me?
Ryan Weispfenning: Yes, we can hear you, Matt.
Matt O’Brien: Yes, okay. Thank you. So just one question, Geoff, for you specifically. It’s — you’re a $30-plus billion revenue company but you talked about more tuck-in acquisitions historically. Just given your size, given the strength in terms of new product flow, I’m just wondering if now is the time to be more aggressive from an M&A perspective just given the pullback that we’ve seen in some of these on the public company side of things, just to be able to do a bigger deal to really solidify your growth algorithm going forward. Is now the time to be more aggressive? Are you more amenable to doing bigger deals now, just given strong balance sheet, kind of got the operating model together, et cetera? Thank you.
Geoff Martha: Yes. Thanks for the question, Matt. And yes, clearly, I think you’re seeing asset prices come down. And it’s a tough operating environment. I think they’re going to continue to come down, in the mid-cap space in particular and below. And we definitely have the capabilities, as you pointed out, to do bigger deals. All that being said, our focus still is on tuck-ins. And we’ve got a lot of big organic — or now organic programs between just Ardian, the robot, PFA, diabetes, I mean, the list goes on. There’s a lot of big organic pipeline going up against these high-growth markets that we’re really focused on. And I would augment that with the appropriate tuck-ins. So I’m not going to — I don’t think we’re really focused on, and we’re not going to signal that we’re focused on any kind of bigger deals at this point.
Ryan Weispfenning: Okay, thanks, Matt. I think we have time. I know we’re running a little bit long, but let’s take two more questions, please, Brad.
Brad Welnick: The next question comes from Rich Newitter at Truist. Rick, please go ahead.
Rich Newitter: Hi, thanks for taking the questions. Just on — we saw just more broadly in medtech a little bit of seasonality or weaker, I think, third quarter for a number of your competitors play out. Just wondering if you could comment on the trend throughout the quarter? Was August unseasonally, kind of, weaker than what you would have thought? And what’s been the normal pickup? Is it stronger-than-expected into the 4Q, especially if you could talk about kind of exit trends from September into October? Thank you.
Geoff Martha: Sure. Thanks for the question, Rich. I’m going to ask Karen to answer that one.
Karen Parkhill: Yes. Thanks, Rich. I would say we saw strength throughout the second quarter no matter what month you looked at. And I think that’s driven in part by just the strength of our product offering. When we look at the first few weeks of this quarter and how that’s been trending, it’s been trending well. We’re tracking to the expectations that we set in our guidance at this stage.
Rich Newitter: Thank you.
Ryan Weispfenning: Thanks, Rich. We’ll take the lasty question, please Brad.
Brad Welnick: Final question comes from Shagun Singh from RBC Capital Markets. Shagun, please go ahead.
